RTL AdConnect & TVSquared Partner to Bring Always-On Proof of Performance to European Broadcast TV Campaigns
9.1.2020 11:00:00 EET | Business Wire | Press release
TVSquared the global leader in TV attribution, and RTL AdConnect, the international Total Video sales house of RTL Group – a leader across broadcast, content and digital – have partnered to provide RTL AdConnect’s global advertisers with always-on proof of performance across more than 150 TV channels and BVOD (broadcaster VOD) platforms throughout Europe. This marks the first time a media owner has launched a European TV attribution initiative for advertisers.
RTL AdConnect’s global advertiser base can now leverage TVSquared’s always-on attribution platform to understand the same-day performance of campaigns airing across RTL’s broadcast channels, which reach 160 million consumers in 12 countries each day. From a single platform, advertisers can evaluate TV performance by day, daypart, creative, program, station and region. Working with RTL AdConnect, they can use those insights to inform optimizations that will maximize business-specific KPIs, including sales, website traffic, search, app activity, call center/SMS response and more.
“This partnership brings together the best of TV’s reach and campaign performance,” said Stéphane Coruble, Managing Director, RTL AdConnect. “Brands that want to expand from U.S. into Europe can take advantage of RTL’s massive broadcast and digital footprint, and measure the same-day impact of those single- or multi-country campaigns via TVSquared’s global platform.”
RTL AdConnect has increased its North American presence significantly in the last two years, helping U.S. brands navigate the complex European TV ad market. Direct-to-consumer (DTC) brands have become one of RTL AdConnect’s fastest-growing customer segments as they look to grow their businesses abroad. By partnering with TVSquared, RTL provides the real-time, transparent performance analytics that digital-native DTCs have come to expect for all media channels, including TV.
“RTL AdConnect is bringing a level of transparency and accountability never before available for European TV advertisers,” said Calum Smeaton, CEO, TVSquared. “We have seen many of our U.S. DTC clients begin to explore European expansion, and this partnership is an easy and impactful way to launch into that valuable market. Whether a brand is running a campaign in one country or multiple, they can enjoy the reach TV brings, while also understanding and optimizing its direct impact on business outcomes.”
About TVSquared
TVSquared is the largest global enterprise platform for linear and digital TV attribution. TVSquared’s always-on analytics platform empowers brands, agencies, networks and publishers to quantify TV’s impact, tie TV to business outcomes and optimize ad performance across TV everywhere. Thousands of advertisers in more than 70 countries work with TVSquared to measure TV across millions of households and billions of ad impressions. Learn more at www.tvsquared.com.
About RTL AdConnect
RTL AdConnect is the international Total Video sales house of RTL Group and beyond. It provides international advertisers a simplified access to a global premium and brand-safe total video inventory ensuring that the right media decisions are made for European campaigns. Thanks to its media partners from RTL Group and beyond, RTL AdConnect reaches around 165+ million potential consumers in Europe every day. RTL AdConnect offers exclusive solutions around high quality content across an extensive portfolio of media partners consisting of more than 150+ TV channels, 500+ digital platforms and 30+ radio stations in 12 countries. With 360-degree solutions, RTL AdConnect supports brands on every step of the way, offering full support from start to finish, ensuring high reach, deep market insights and cross-screen solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005104/en/
Contact information
Media:
Megan Garnett Coyle
TVSquared
+1 347 603 5096
megan@tvsquared.com
Carine Jean-Jean
RTL AdConnect
+33 6 30 51 58 73
cjeanjean@rtladconnect.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom